X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   MYLAN
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
MYLAN
Dec-14
NATCO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8773,805-   
Low Rs4242,682-   
Sales per share (Unadj.) Rs223.41,302.8-  
Earnings per share (Unadj.) Rs31.1156.9-  
Cash flow per share (Unadj.) Rs40.3252.6-  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.5647.6-  
Shares outstanding (eoy) m33.07378.37-   
Bonus/Rights/Conversions PAOI-  
Price / Sales ratio x2.92.5 116.9%   
Avg P/E ratio x20.920.7 101.3%  
P/CF ratio (eoy) x16.112.8 125.8%  
Price / Book Value ratio x3.05.0 59.1%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5041,227,273 1.8%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m1,1280-   
Avg. sales/employee Rs ThNM19,716.9-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,375.2-  
INCOME DATA
Net Sales Rs m7,389492,922 1.5%  
Other income Rs m167-2,873 -5.8%   
Total revenues Rs m7,556490,049 1.5%   
Gross profit Rs m1,793122,592 1.5%  
Depreciation Rs m30436,203 0.8%   
Interest Rs m36621,262 1.7%   
Profit before tax Rs m1,29062,254 2.1%   
Minority Interest Rs m46-255 -18.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3092,618 11.8%   
Profit after tax Rs m1,02759,381 1.7%  
Gross profit margin %24.324.9 97.6%  
Effective tax rate %23.94.2 569.2%   
Net profit margin %13.912.0 115.4%  
BALANCE SHEET DATA
Current assets Rs m3,681433,344 0.8%   
Current liabilities Rs m3,123338,788 0.9%   
Net working cap to sales %7.619.2 39.4%  
Current ratio x1.21.3 92.2%  
Inventory Days Days8978 114.6%  
Debtors Days Days59107 54.7%  
Net fixed assets Rs m7,685114,036 6.7%   
Share capital Rs m33117,431 1.9%   
"Free" reserves Rs m6,6700-   
Net worth Rs m7,259245,031 3.0%   
Long term debt Rs m955366,052 0.3%   
Total assets Rs m11,957986,961 1.2%  
Interest coverage x4.53.9 115.1%   
Debt to equity ratio x0.11.5 8.8%  
Sales to assets ratio x0.60.5 123.7%   
Return on assets %11.78.2 142.6%  
Return on equity %14.224.2 58.4%  
Return on capital %20.713.6 152.1%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,44064,795 2.2%  
From Investments Rs m-1,089-51,099 2.1%  
From Financial Activity Rs m-353-17,073 2.1%  
Net Cashflow Rs m-1-3,378 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare NATCO PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: PANACEA BIOTECH  IPCA LABS  ELDER PHARMA  PIRAMAL ENTERPRISES  STERLING BIOTECH  



Today's Market

Sensex Trades in Green; IT Stocks Top Gainers(01:30 pm)

After opening the day marginally higher, share markets in India continued the momentum and are presently trading in green. Sectoral indices are trading on a mixed note, with stocks in the IT sector.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 22, 2018 03:33 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - STRIDES SHASUN LTD COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS